Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine.
Capecitabine, an oral fluoropyrimidine and 5-fluorouracil (FU) prodrug recently approved for the treatment of metastatic colon and breast cancer, is currently under investigation in patients with gastric cancer. It has the advantage of oral administration, and good tolerability with its activity being comparable with intravenous 5-FU. Lupus erythematosus and lupuslike drug eruptions have been observed after 5-FU treatment, but so far no cases of subacute cutaneous lupus erythematosus have been described in patients treated either with capecitabine or 5-FU. We report a patient who developed subacute cutaneous lupus erythematosus after administration of 5-FU and capecitabine.
Weger
Wolfgang
W
Department of Dermatology, Medical University of Graz, Graz, Austria.
Kränke
Birger
B
Gerger
Armin
A
Salmhofer
Wolfgang
W
Aberer
Elisabeth
E
D000208:Acute Disease; D000284:Administration, Oral; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D017809:Fatal Outcome; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced* / Q000188:drug therapy; D012720:Severity of Illness Index; D013256:Steroids / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000188:drug therapy*
D000964:Antimetabolites, Antineoplastic; D013256:Steroids; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil